Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party

We investigated >= grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The...

Full description

Bibliographic Details
Authors: Penack, Olaf, Peczynski, Christophe, Koenecke, Christian, Polge, Emmanuelle, Sanderson, Robin, Yakoub Agha, Ibrahim, Fegueux, Nathalie, Daskalakis, Michael, Collin, Matthew, Dreger, Peter, Kröger, Nicolaus, Schanz, Urs, Bloor, Adrian, Ganser, Arnold, Besley, Caroline, Wulf, Gerald G., Novak, Urban, Moiseev, Ivan, Schoemans, Hélène, Basak, Grzegorz W., Chabannon, Christian, Sureda, Anna, Glass, Bertram, Peric, Zinaida
Format: article
Status:Published version
Publication Date:2023
Country:España
Institution:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/208421
Online Access:https://hdl.handle.net/2445/208421
Access Level:Open access
Keyword:Limfomes
Receptors cel·lulars
Lymphomas
Cell receptors
id ES_f75c247fe20747eec8ad3e55fd61371a
oai_identifier_str oai:recercat.cat:2445/208421
network_acronym_str ES
network_name_str España
repository_id_str
spelling Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working partyPenack, OlafPeczynski, ChristopheKoenecke, ChristianPolge, EmmanuelleSanderson, RobinYakoub Agha, IbrahimFegueux, NathalieDaskalakis, MichaelCollin, MatthewDreger, PeterKröger, NicolausSchanz, UrsBloor, AdrianGanser, ArnoldBesley, CarolineWulf, Gerald G.Novak, UrbanMoiseev, IvanSchoemans, HélèneBasak, Grzegorz W.Chabannon, ChristianSureda, AnnaGlass, BertramPeric, ZinaidaLimfomesReceptors cel·lularsLymphomasCell receptorsWe investigated >= grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of >= grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting.Frontiers Media SA2024202420232023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion10 p.application/pdfhttps://hdl.handle.net/2445/208421Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.3389/fimmu.2023.1252811Frontiers in Immunology, 2023, vol. 14https://doi.org/10.3389/fimmu.2023.1252811cc by (c) Penack, Olaf et al., 2023http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/2084212026-05-29T05:05:01Z
dc.title.none.fl_str_mv Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
title Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
spellingShingle Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
Penack, Olaf
Limfomes
Receptors cel·lulars
Lymphomas
Cell receptors
title_short Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
title_full Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
title_fullStr Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
title_full_unstemmed Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
title_sort Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party
dc.creator.none.fl_str_mv Penack, Olaf
Peczynski, Christophe
Koenecke, Christian
Polge, Emmanuelle
Sanderson, Robin
Yakoub Agha, Ibrahim
Fegueux, Nathalie
Daskalakis, Michael
Collin, Matthew
Dreger, Peter
Kröger, Nicolaus
Schanz, Urs
Bloor, Adrian
Ganser, Arnold
Besley, Caroline
Wulf, Gerald G.
Novak, Urban
Moiseev, Ivan
Schoemans, Hélène
Basak, Grzegorz W.
Chabannon, Christian
Sureda, Anna
Glass, Bertram
Peric, Zinaida
author Penack, Olaf
author_facet Penack, Olaf
Peczynski, Christophe
Koenecke, Christian
Polge, Emmanuelle
Sanderson, Robin
Yakoub Agha, Ibrahim
Fegueux, Nathalie
Daskalakis, Michael
Collin, Matthew
Dreger, Peter
Kröger, Nicolaus
Schanz, Urs
Bloor, Adrian
Ganser, Arnold
Besley, Caroline
Wulf, Gerald G.
Novak, Urban
Moiseev, Ivan
Schoemans, Hélène
Basak, Grzegorz W.
Chabannon, Christian
Sureda, Anna
Glass, Bertram
Peric, Zinaida
author_role author
author2 Peczynski, Christophe
Koenecke, Christian
Polge, Emmanuelle
Sanderson, Robin
Yakoub Agha, Ibrahim
Fegueux, Nathalie
Daskalakis, Michael
Collin, Matthew
Dreger, Peter
Kröger, Nicolaus
Schanz, Urs
Bloor, Adrian
Ganser, Arnold
Besley, Caroline
Wulf, Gerald G.
Novak, Urban
Moiseev, Ivan
Schoemans, Hélène
Basak, Grzegorz W.
Chabannon, Christian
Sureda, Anna
Glass, Bertram
Peric, Zinaida
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Limfomes
Receptors cel·lulars
Lymphomas
Cell receptors
topic Limfomes
Receptors cel·lulars
Lymphomas
Cell receptors
description We investigated >= grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of >= grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting.
publishDate 2023
dc.date.none.fl_str_mv 2023
2023
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/208421
url https://hdl.handle.net/2445/208421
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2023.1252811
Frontiers in Immunology, 2023, vol. 14
https://doi.org/10.3389/fimmu.2023.1252811
dc.rights.none.fl_str_mv cc by (c) Penack, Olaf et al., 2023
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Penack, Olaf et al., 2023
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 10 p.
application/pdf
dc.publisher.none.fl_str_mv Frontiers Media SA
publisher.none.fl_str_mv Frontiers Media SA
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424875921211392
score 15,812429

Similar Items